Telix Pharmaceuticals (TLX) Intangibles (2023 - 2024)

Telix Pharmaceuticals (TLX) has reported Intangibles for 3 consecutive years, with $592.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Intangibles rose 117.84% year-over-year to $592.8 million; the TTM figure through Dec 2025 stood at $592.8 million (up 117.84% YoY), while the FY2025 annual figure was $592.8 million, up 129.9% from the prior year.
• Intangibles advanced to $592.8 million in Q4 2025 per TLX's latest filing, from $272.1 million in the prior quarter.
• Across five years, Intangibles topped out at $592.8 million in Q4 2025 and bottomed at $71.4 million in Q4 2023.
• Historically, Intangibles has averaged $312.1 million across 3 years, with a median of $272.1 million in 2024.
• Annual changes were most pronounced in 2024 — Intangibles surged 281.2% — and 2025, when it surged 117.84%.
• Telix Pharmaceuticals' Intangibles stood at $71.4 million in 2023, then soared by 281.2% to $272.1 million in 2024, then soared by 117.84% to $592.8 million in 2025.
• Business Quant data shows TLX's Intangibles at $592.8 million in Q4 2025, $272.1 million in Q4 2024, and $71.4 million in Q4 2023.